New York State Common Retirement Fund Grows Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

New York State Common Retirement Fund boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 37.0% during the fourth quarter, Holdings Channel reports. The firm owned 72,866 shares of the biopharmaceutical company’s stock after buying an additional 19,673 shares during the quarter. New York State Common Retirement Fund’s holdings in Ultragenyx Pharmaceutical were worth $3,484,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of RARE. SG Americas Securities LLC grew its holdings in Ultragenyx Pharmaceutical by 390.4% during the 3rd quarter. SG Americas Securities LLC now owns 12,156 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 9,677 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in Ultragenyx Pharmaceutical by 127.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 22,108 shares of the biopharmaceutical company’s stock worth $788,000 after purchasing an additional 12,403 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Ultragenyx Pharmaceutical by 19.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,136 shares of the biopharmaceutical company’s stock valued at $504,000 after purchasing an additional 2,292 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ultragenyx Pharmaceutical by 9.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 210,968 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 18,845 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in shares of Ultragenyx Pharmaceutical by 74.4% during the 3rd quarter. TD Asset Management Inc now owns 205,360 shares of the biopharmaceutical company’s stock worth $7,321,000 after purchasing an additional 87,580 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Down 1.0 %

Shares of Ultragenyx Pharmaceutical stock opened at $42.75 on Monday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $31.52 and a 1 year high of $54.98. The company’s fifty day simple moving average is $47.25 and its 200-day simple moving average is $44.22. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -5.32 and a beta of 0.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million during the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.33) EPS. As a group, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RARE shares. Wedbush decreased their target price on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday. Royal Bank of Canada initiated coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price objective for the company. Canaccord Genuity Group upped their target price on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. JPMorgan Chase & Co. raised their price target on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Finally, TD Cowen raised their target price on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $88.00.

Insider Buying and Selling

In other news, EVP Karah Herdman Parschauer sold 3,756 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $201,922.56. Following the transaction, the executive vice president now directly owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the sale, the insider now owns 89,268 shares in the company, valued at $4,799,047.68. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 3,756 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $201,922.56. Following the completion of the sale, the executive vice president now owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The disclosure for this sale can be found here. Insiders sold a total of 32,116 shares of company stock worth $1,645,983 over the last three months. 6.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.